Real-world treatment practices of selexipag and parenteral prostacyclin (PGI2) analogs for pulmonary arterial hypertension in Japan: Retrospective study of the Japan PH Registry
Parenteral PGI<sub>2</sub> analogs tend to be used mainly in patients with severe IPAH/HPAH, while selexipag is used in patients with a broader range of etiologies around NYHA-FC II-III. Choice of selexipag and parenteral PGI<sub>2</sub> analogs for treatment of PAH is influenced by disease severity and etiology.
Authors
- Ayako Shigeta (ORCID: https://orcid.org/0000-0002-4536-4487)
- Yu Taniguchi (ORCID: https://orcid.org/0000-0002-8430-2123)
- Junichi Nakamura (ORCID: https://orcid.org/0000-0003-4005-8832)
- Seiya Ohtani
- Kohji Murakami
- Hiraku Kumamaru
- Takumi Inami
- Yuichi Tamura
- Kohtaro Abe
- Hiromi Matsubara
- Koichi Matsuoka
Institutions
- Chiba University (JP)
- Hokkaido University (JP)
- Kyushu University Hospital (JP)
- National Hospital Organization (JP)
- Kyorin University Hospital (JP)
- Okayama Medical Center (JP)
- Mita Hospital (JP)
- Nippon Shinyaku (Japan) (JP)
- Kobe University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Journal of Cardiology
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1016/j.jjcc.2025.12.022
- Citations
- 2
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 72.89